Literature DB >> 27790552

Comparative Evaluation of Volatile Anaesthetic Agents for Attenuation of Venous Cannulation Pain: A Prospective, Randomized Controlled Study.

Vinit K Srivastava1, Pravin K Das2, Sujeet Ks Gautam3, Parineeta Jaisawal4, Venkat N Kadiyala5, Sonal Rambhad5.   

Abstract

INTRODUCTION: Topical application of volatile anaesthetic agents has been found to attenuate the response to a mechanical stimulus; however, this effect of volatile anaesthetic on perception of pain during venous cannulation is not known. AIM: To compare the efficacy of topically administered volatile anaesthetic agents for attenuating venous cannulation pain.
MATERIALS AND METHODS: This prospective, randomized, placebo controlled and double blind study was conducted on 120 patients, aged 20-60years. They were of American Society of Anaesthesiologists (ASA) I or II physical status, of either sex, planned for elective surgeries. These patients were randomized into 4 groups, of 30 each. Equipotent doses of halothane (1ml), isoflurane (1.5ml), sevoflurane (2.7ml) and sterile water (2.5ml; Control) were topically administered on the volar surface of forearm wrapped with cotton and aluminium foil; venous cannulation was performed with 18G intravenous cannula after 30 min. These patients were assessed for the incidence and severity of pain upon venous cannulation {visual analog scale (VAS), 0-100mm; 0 = no pain and 100 = worst imaginable pain}. Data were analysed by one-way ANOVA, Chi-square test and Kruskal-Wallis test. The p<0.05 was considered as significant.
RESULTS: A significant reduction in the incidence of venous cannulation pain was observed in the halothane (79%) group as compared to control (100%; p<0.05), isoflurane (100%; p<0.05) and sevoflurane (100%; p<0.05) groups. The severity of venous cannulation pain as assessed by median (interquartile range, Q1-Q3). VAS scores was reduced in the halothane {10 (10-20); p<0.001}, isoflurane {20 (10-30); p<0.001} and sevoflurane {20 (20-30); p<0.001} groups as compared to the control group {40 (30-40)}; VAS score in the halothane group was significantly less as compared to isoflurane (p<0.05) and sevoflurane (p<0.05) groups.
CONCLUSION: Topical application of halothane is most effective in reducing incidence and severity of venous cannulation pain; however, topical application of isoflurane and sevoflurane decreases only the severity of venous cannulation pain.

Entities:  

Keywords:  Halothane; Isoflurane; Sevoflurane

Year:  2016        PMID: 27790552      PMCID: PMC5072052          DOI: 10.7860/JCDR/2016/19970.8412

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  21 in total

Review 1.  Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration.

Authors:  James M Sonner; Joseph F Antognini; Robert C Dutton; Pamela Flood; Andrew T Gray; R Adron Harris; Gregg E Homanics; Joan Kendig; Beverley Orser; Douglas E Raines; Ira J Rampil; James Trudell; Bryce Vissel; Edmond I Eger
Journal:  Anesth Analg       Date:  2003-09       Impact factor: 5.108

2.  Percutaneous loss of desflurane, isoflurane, and halothane in humans.

Authors:  A Fassoulaki; S H Lockhart; B A Freire; N Yasuda; E I Eger; R B Weiskopf; B H Johnson
Journal:  Anesthesiology       Date:  1991-03       Impact factor: 7.892

3.  Volatile anesthetic sensitivity of T-type calcium currents in various cell types.

Authors:  T S McDowell; J J Pancrazio; P Q Barrett; C Lynch
Journal:  Anesth Analg       Date:  1999-01       Impact factor: 5.108

4.  A comparison of Rapydan® patch and Ametop® gel for venous cannulation.

Authors:  N Ravishankar; S C Elliot; Z Beardow; A Mallick
Journal:  Anaesthesia       Date:  2012-01-23       Impact factor: 6.955

5.  Vapocoolant spray vs subcutaneous lidocaine injection for reducing the pain of intravenous cannulation: a randomized, controlled, clinical trial.

Authors:  D E Page; D McD Taylor
Journal:  Br J Anaesth       Date:  2010-08-03       Impact factor: 9.166

6.  Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by experimentally induced pain.

Authors:  S Petersen-Felix; L Arendt-Nielsen; P Bak; D Roth; M Fischer; P Bjerring; A M Zbinden
Journal:  Br J Anaesth       Date:  1995-07       Impact factor: 9.166

7.  Effects of halothane and enflurane on firing threshold of frog myelinated axons.

Authors:  J F Butterworth; S A Raymond; R F Roscoe
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

8.  Inhaled anesthetics have hyperalgesic effects at 0.1 minimum alveolar anesthetic concentration.

Authors:  Y Zhang; E I Eger; R C Dutton; J M Sonner
Journal:  Anesth Analg       Date:  2000-08       Impact factor: 5.108

9.  A comparative evaluation of local application of the combination of eutectic mixture of local anesthetics and capsaicin for attenuation of venipuncture pain.

Authors:  Devendra Gupta; Kamal Kishore; Sonal Rastogi; Prabhat K Singh; Anil Agarwal; Uttam Singh
Journal:  Anesth Analg       Date:  2013-02-11       Impact factor: 5.108

10.  Effects of a flash of light in different colors on venous cannulation pain: a randomized, controlled trial.

Authors:  Mojgan Rahimi; Jalil Makarem; Pooria Rooyan
Journal:  J Clin Anesth       Date:  2012-12-20       Impact factor: 9.452

View more
  2 in total

1.  Comparison of music and vapocoolant spray in reducing the pain of venous cannulation in children age 6-12: a randomized clinical trial.

Authors:  Masoomeh Ghasemi; Poria Hoseinialiabadi; Fatemeh Yazdanpanah; Maryam Askaryzadeh Mahani; Leila Malekyan; Kazem Najafi; Mohammadreza Arab; Mansour Arab; Hadi Ranjbar
Journal:  BMC Pediatr       Date:  2022-04-29       Impact factor: 2.567

Review 2.  Topical Sevoflurane: A Novel Treatment for Chronic Pain Caused by Venous Stasis Ulcers.

Authors:  Mayank Aranke; Cynthia T Pham; Melis Yilmaz; Jason K Wang; Vwaire Orhurhu; Daniel An; Elyse M Cornett; Alan David Kaye; Anh L Ngo; Farnad Imani; Reza Farahmand Rad; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Anesth Pain Med       Date:  2021-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.